Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.44 +3.5%	$0.39	$0.30 ▼ $10.62	$61.97M	1.82	3.46 million shs	1.13 million shs
ARCT Arcturus Therapeutics	$12.85 -2.3%	$12.66	$8.04 ▼ $25.88	$348.49M	2.27	416,915 shs	354,231 shs
ENTA Enanta Pharmaceuticals	$7.09 +7.6%	$6.73	$4.09 ▼ $16.73	$151.58M	0.84	279,944 shs	215,697 shs
INVVY Indivior	$21.85 -1.8%	$21.85	$14.76 ▼ $35.50	$3.01B	0.35	3,825 shs	8,100 shs
PHAT Phathom Pharmaceuticals	$8.33 -2.5%	$7.04	$2.21 ▼ $19.71	$581.55M	0.45	1.55 million shs	1.68 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	+0.40%	+14.55%	+19.41%	+39.14%	-92.88%
ARCT Arcturus Therapeutics	-1.20%	-4.71%	+6.22%	+27.67%	-43.76%
ENTA Enanta Pharmaceuticals	-5.32%	-14.97%	-12.13%	+33.67%	-60.16%
INVVY Indivior	0.00%	0.00%	0.00%	0.00%	0.00%
PHAT Phathom Pharmaceuticals	-5.74%	-5.32%	-19.74%	+102.37%	-32.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.538 of 5 stars	3.3	3.0	0.0	4.7	3.8	1.7	1.3
ARCT Arcturus Therapeutics	1.9753 of 5 stars	3.6	0.0	0.0	0.0	2.1	2.5	0.6
ENTA Enanta Pharmaceuticals	3.9251 of 5 stars	3.4	1.0	0.0	4.7	3.1	2.5	0.0
INVVY Indivior	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	4.1824 of 5 stars	4.5	4.0	0.0	0.0	1.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,293.65% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	320.23% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	153.88% Upside
INVVY Indivior	0.00	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	110.08% Upside

Current Analyst Ratings Breakdown

Latest INVVY, PHAT, ARCT, APLT, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$265K	233.84	N/A	N/A	$0.49 per share	0.89
ARCT Arcturus Therapeutics	$152.31M	2.29	N/A	N/A	$8.90 per share	1.44
ENTA Enanta Pharmaceuticals	$67.64M	2.24	N/A	N/A	$6.08 per share	1.17
INVVY Indivior	$791M	3.81	$1.15 per share	18.94	$1.45 per share	15.07
PHAT Phathom Pharmaceuticals	$81.86M	7.10	N/A	N/A	($3.71) per share	-2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
INVVY Indivior	$205M	$1.05	20.81	12.00	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)

Latest INVVY, PHAT, ARCT, APLT, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INVVY Indivior	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	3.00	3.00
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
INVVY Indivior	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
ARCT Arcturus Therapeutics	94.54%
ENTA Enanta Pharmaceuticals	94.99%
INVVY Indivior	0.05%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
ARCT Arcturus Therapeutics	15.30%
ENTA Enanta Pharmaceuticals	13.89%
INVVY Indivior	N/A
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
INVVY Indivior	800	137.88 million	N/A	Not Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	52.99 million	Optionable

INVVY, PHAT, ARCT, APLT, and ENTA Headlines

Recent News About These Companies

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6% - Should You Sell?

July 15 at 2:45 PM | marketbeat.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from Brokerages

July 13 at 6:05 AM | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.4% - Here's What Happened

July 7, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's Why

July 1, 2025 | marketbeat.com

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

June 25, 2025 | seekingalpha.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - Morningstar

June 24, 2025 | morningstar.comM

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

June 23, 2025 | news.bloomberglaw.comN

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?

June 23, 2025 | marketbeat.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by Brokerages

June 18, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025 | globenewswire.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 8, 2025 | finanznachrichten.de

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock

June 7, 2025 | investing.com

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

June 6, 2025 | msn.com

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

June 6, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVVY, PHAT, ARCT, APLT, and ENTA Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.44 +0.02 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$0.43 -0.01 (-1.53%)

As of 06:32 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Arcturus Therapeutics NASDAQ:ARCT

$12.85 -0.30 (-2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$13.02 +0.17 (+1.28%)

As of 06:38 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.09 +0.50 (+7.59%)

Closing price 04:00 PM Eastern

Extended Trading

$7.62 +0.53 (+7.48%)

As of 06:43 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Indivior OTCMKTS:INVVY

$21.85 -0.40 (-1.82%)

As of 06/9/2023

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Phathom Pharmaceuticals NASDAQ:PHAT

$8.33 -0.21 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$8.39 +0.06 (+0.72%)

As of 06:02 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time